β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from QatarShow others and affiliations
2020 (English)In: Antimicrobial Resistance and Infection Control, E-ISSN 2047-2994, Vol. 9, no 1, article id 170
Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: The distribution of β-lactam resistance genes in P. aeruginosa is often closely related to the distribution of certain high-risk international clones. We used whole-genome sequencing (WGS) to identify the predominant sequence types (ST) and β-lactamase genes in clinical isolates of multidrug-resistant (MDR)-P. aeruginosa from Qatar METHODS: Microbiological identification and susceptibility tests were performed by automated BD Phoenix™ system and manual Liofilchem MIC Test Strips.
RESULTS: Among 75 MDR-P. aeruginosa isolates; the largest proportions of susceptibility were to ceftazidime-avibactam (n = 36, 48%), followed by ceftolozane-tazobactam (30, 40%), ceftazidime (n = 21, 28%) and aztreonam (n = 16, 21.3%). All isolates possessed Class C and/or Class D β-lactamases (n = 72, 96% each), while metallo-β-lactamases were detected in 20 (26.7%) isolates. Eight (40%) metallo-β-lactamase producers were susceptible to aztreonam and did not produce any concomitant extended-spectrum β-lactamases. High risk ST235 (n = 16, 21.3%), ST357 (n = 8, 10.7%), ST389 and ST1284 (6, 8% each) were most frequent. Nearly all ST235 isolates (15/16; 93.8%) were resistant to all tested β-lactams.
CONCLUSION: MDR-P. aeruginosa isolates from Qatar are highly resistant to antipseudomonal β-lactams. High-risk STs are predominant in Qatar and their associated MDR phenotypes are a cause for considerable concern.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2020. Vol. 9, no 1, article id 170
Keywords [en]
Beta-lactamases, MDR, P. aeruginosa, ST235
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:oru:diva-87218DOI: 10.1186/s13756-020-00838-yISI: 000583667500001PubMedID: 33131487Scopus ID: 2-s2.0-85094899717OAI: oai:DiVA.org:oru-87218DiVA, id: diva2:1499032
Funder
Swedish Research Council Formas, 219-2014-837
Note
Funding Agencies:
Medical Research Centre at Hamad Medical Corporation, Doha, Qatar IRGC-01-51-033
NPRP from the Qatar National Research Fund (a member of Qatar Foundation) NPRP12S-0219-190109
2020-11-062020-11-062023-06-28Bibliographically approved